stockportfolio.pro
Fortrea Holdings Inc. (FTRE)
Healthcare · Biotechnology · NasdaqGS
Fortrea Holdings Inc. revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.06B | $2.84B | $3.11B | $2.70B | $2.72B |
| Gross profit | — | — | — | — | — |
| Net income | $98.00M | $192.90M | $-3.40M | $-328.50M | $-986.20M |
| Net margin | 3.2% | 6.8% | -0.1% | -12.2% | -36.2% |
Source: Fortrea Holdings Inc. SEC filings (10-K).
What growth is priced into FTRE stock?
At today's market cap of $1.57B, Fortrea Holdings Inc. is priced for free-cash-flow growth of about 6.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $88.30M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 5 years of Fortrea Holdings Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track FTRE in your portfolio →
Fortrea Holdings Inc. financial history by metric
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Fortrea Holdings Inc. — frequently asked questions
What is Fortrea Holdings Inc.'s revenue?
Fortrea Holdings Inc. (FTRE) reported revenue of $2.72B for fiscal year 2025, up 1.0% from the prior year, according to its SEC filings.
Is Fortrea Holdings Inc. profitable?
No — FTRE reported a net loss of $-986.20M in fiscal 2025.
What is FTRE's P/E ratio?
Fortrea Holdings Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Fortrea Holdings Inc. growing?
FTRE's revenue grew at roughly -2.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Fortrea Holdings Inc. have?
As of fiscal year 2025, FTRE carried roughly $1.05B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Fortrea Holdings Inc.'s market cap?
Fortrea Holdings Inc. (FTRE) has a market capitalization of about $1.57B, based on the latest data in our nightly-refreshed cache.
When does Fortrea Holdings Inc.'s fiscal year end?
FTRE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into FTRE stock?
At today's market cap of $1.57B, Fortrea Holdings Inc. is priced for free-cash-flow growth of about 6.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $88.30M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from Fortrea Holdings Inc.'s official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.